Monopar Therapeutics IncNASDAQ:MNPR
- LAST PRICE20.1000
- TODAY'S CHANGE (%)0.3900 (1.9787%)
- Bid / Lots19.5000/ 2
- Ask / Lots21.0000/ 3
- Open / Previous Close19.8800 / 19.7100
- Day Range
- 52 Week Range
- Volume32,547
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MNPR |
|---|---|---|
| 09:32 ET | 330 | 19.88 |
| 09:33 ET | 300 | 19.56 |
| 09:35 ET | 200 | 20.15 |
| 10:04 ET | 200 | 19.965 |
| 11:00 ET | 100 | 19.66 |
| 11:05 ET | 100 | 19.75 |
| 11:12 ET | 5328 | 19.7 |
| 11:14 ET | 100 | 19.62 |
| 11:20 ET | 200 | 19.75 |
| 11:25 ET | 200 | 19.75 |
| 11:27 ET | 100 | 19.75 |
| 11:32 ET | 250 | 19.75 |
| 11:34 ET | 100 | 19.75 |
| 11:43 ET | 110 | 19.75 |
| 12:01 ET | 100 | 19.86 |
| 12:10 ET | 114 | 19.82 |
| 12:14 ET | 200 | 19.775 |
| 12:15 ET | 100 | 19.75 |
| 12:26 ET | 100 | 19.71 |
| 12:42 ET | 200 | 19.73 |
| 12:57 ET | 353 | 19.73 |
| 01:04 ET | 100 | 20 |
| 01:06 ET | 281 | 19.6541 |
| 01:24 ET | 909 | 20 |
| 01:29 ET | 100 | 19.8418 |
| 01:44 ET | 100 | 19.86 |
| 01:51 ET | 100 | 20 |
| 02:09 ET | 1100 | 19.865 |
| 02:12 ET | 820 | 19.75 |
| 02:20 ET | 400 | 19.75 |
| 02:50 ET | 115 | 19.765 |
| 02:52 ET | 100 | 19.835 |
| 03:24 ET | 100 | 19.835 |
| 03:42 ET | 100 | 19.81 |
| 03:48 ET | 203 | 20 |
| 03:50 ET | 428 | 20 |
| 03:51 ET | 328 | 20 |
| 03:53 ET | 100 | 19.98 |
| 03:55 ET | 200 | 19.99 |
| 03:57 ET | 200 | 19.98 |
| 04:00 ET | 4467 | 20.1 |
Nov 11, 2024
DJ Monopar Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 12:34PM ET on Monday Nov 11, 2024 by Dow Jones
12:34PM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments, from 8:00AM ET on Friday Nov 08, 2024 by Dow Jones
8:00AM ET on Friday Nov 08, 2024 by Dow JonesPress Release: Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments, from 8:00AM ET on Friday Nov 08, 2024 by Dow Jones
8:00AM ET on Friday Nov 08, 2024 by Dow Jones
Oct 30, 2024
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock, from 1:42PM ET on Wednesday Oct 30, 2024 by Dow Jones
1:42PM ET on Wednesday Oct 30, 2024 by Dow JonesPress Release: Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock, from 1:42PM ET on Wednesday Oct 30, 2024 by Dow Jones
1:42PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Monopar Therapeutics Inc | 104.0M | -10.1x | --- |
INmune Bio Inc | 105.5M | -2.2x | --- |
Tiziana Life Sciences Ltd | 107.3M | -5.5x | --- |
Immunic Inc | 100.0M | -0.9x | --- |
Leap Therapeutics Inc | 98.7M | -1.3x | --- |
Rani Therapeutics Holdings Inc | 109.4M | -2.0x | --- |
Company Information
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Contact Information
- Headquarters
- 1000 Skokie Blvd Ste 350WILMETTE, IL, United States 60091-1146
- Phone
- 847-388-0349
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Christopher Starr
- Chief Executive Officer, Director
- Chandler Robinson
- Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer
- Karthik Radhakrishnan
- Chief Operating Officer
- Andrew Cittadine
- Acting Chief Medical Officer
- Patrice Rioux
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $104.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.16 |
EPS | $-1.99 |
Book Value | $1.87 |
P/E Ratio | -10.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
